» Articles » PMID: 8667921

Duration and Intensity of Maintenance Chemotherapy in Acute Lymphoblastic Leukaemia: Overview of 42 Trials Involving 12 000 Randomised Children

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1996 Jun 29
PMID 8667921
Citations 40
Affiliations
Soon will be listed here.
Abstract

Background: The effects on long-term outcome in childhood acute lymphoblastic leukaemia (ALL) of the duration and the intensity of maintenance chemotherapy need to be assessed reliably. With this objective the Childhood ALL Collaborative Group coordinated a worldwide overview of all randomised trials that began before 1987.

Methods: Individual patient data were sought for about 3900 children in trials of longer vs shorter maintenance (eg, 3 vs 2 years), 3700 in trials of intensive "reinduction" chemotherapy during maintenance, and 4400 in trials of various other questions, including 1300 in trials of pulses of vincristine and prednisone (VP) during maintenance. Analyses were of survival in first remission, overall survival, and cause-specific mortality.

Findings: Deaths during remission were increased by longer maintenance (2.7 percent vs 1.2 percent), VP pulses (4.0 vs 3.2 percent), and intensive reinduction (4.8 percent vs 3.3 percent), but these increases were counterbalanced by reductions in relapses. Total events (relapse or death) were significantly reduced by longer maintenance (23.3 percent vs 27.6 percent), VP pulses (31.2 percent vs 40.4 percent) and intensive reinduction (27.8 percent vs 35.8 percent) (each 2p<0.001). Many of those who relapsed were successfully re-treated, however, and only for intensive reinduction was overall survival significantly improved (18.5 percent vs 22.3 percent; 2p=0.01).

Interpretation: Intensive reinduction chemotherapy in these trials produced an absolute improvement of about 4 percent in long-term survival; if the extra deaths in remission had been avoided, this would have been a 5 percent benefit. Further improvements in survival seem more likely to be obtained with intensive treatment than with longer low-level maintenance.

Citing Articles

Individual participant data (IPD) meta-analysis: An introduction - Narrative review.

Rai E, Naik V, Williams A, Kamath M Indian J Anaesth. 2025; 69(1):153-160.

PMID: 40046704 PMC: 11878366. DOI: 10.4103/ija.ija_1187_24.


JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.

Kato M, Okamoto Y, Imamura T, Kada A, Saito A, Iijima-Yamashita Y J Clin Oncol. 2024; 43(5):567-577.

PMID: 39531610 PMC: 11809717. DOI: 10.1200/JCO.24.00811.


Tooth Abnormalities and Their Age-Dependent Occurrence in Leukemia Survivors.

Jodlowska A, Postek-Stefanska L Cancers (Basel). 2023; 15(22).

PMID: 38001680 PMC: 10670488. DOI: 10.3390/cancers15225420.


Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma.

Li Z, Zhang B, Fan X, Gui R, Yu F, Wang J Front Oncol. 2023; 13:1193237.

PMID: 37546390 PMC: 10399448. DOI: 10.3389/fonc.2023.1193237.


Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021.

Bai L, Zhan Y, Zhou Y, Zhang Y, Shi L, Gupta S EClinicalMedicine. 2023; 59:101966.

PMID: 37125406 PMC: 10130597. DOI: 10.1016/j.eclinm.2023.101966.